Methotrexate leukoencephalopathy presenting as Kluver-Bucy syndrome and uncinate seizures

被引:23
作者
Antunes, NL
Souweidane, MM
Rosenblum, MK
Steinherz, PG
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
D O I
10.1016/S0887-8994(01)00376-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Methotrexate causes several biochemical changes that impact the nervous system. The neurotoxicity usually affects the cerebral white matter, causing a leukoencephalopathy that can be chronic and progressive with cognitive decline. A 15-year-old male developed olfactory seizures and behavioral abnormalities (hypersexuality, placidity, and memory disturbances) compatible with partial Kluver-Bucy syndrome after treatment for central nervous system leukemia with intraventricular methotrexate. A magnetic resonance imaging study revealed evidence of white matter disease affecting both temporal lobes. A brain biopsy revealed a necrotizing encephalopathy compatible with methotrexate-related white matter injury. It may be prudent to verify normal cerebrospinal fluid dynamics before the administration of intraventricular methotrexate in children with a history of central nervous system leukemia. (C) 2002 by Elsevier Science Inc. All rights reserved.
引用
收藏
页码:305 / 308
页数:4
相关论文
共 17 条
[11]  
LILLY R, 1983, NEUROLOGY, V33, P1141, DOI 10.1212/WNL.33.9.1141
[12]  
Longo-Sorbello GSA, 2001, HAEMATOLOGICA, V86, P121
[13]   ACUTE ASCENDING MYELITIS AND ENCEPHALOPATHY AFTER INTRATHECAL CYTOSINE-ARABINOSIDE AND METHOTREXATE IN AN ADOLESCENT BOY WITH ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
OZON, A ;
TOPALOGLU, H ;
CILA, A ;
GUNAY, M ;
CETIN, M .
BRAIN & DEVELOPMENT, 1994, 16 (03) :246-248
[14]   Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSP of children who receive methotrexate for the treatment of cancer [J].
Quinn, CT ;
Griener, JC ;
Bottiglieri, T ;
Hyland, K ;
Farrow, A ;
Kamen, BA .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) :2800-2806
[15]   METHOTREXATE - DISTRIBUTION IN CEREBROSPINAL-FLUID AFTER INTRAVENOUS, VENTRICULAR AND LUMBAR INJECTIONS [J].
SHAPIRO, WR ;
YOUNG, DF ;
MEHTA, BM .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 293 (04) :161-166
[16]   Methotrexate treatment protocols and the central nervous system: Significant cure with significant neurotoxicity [J].
Shuper, A ;
Stark, B ;
Kornreich, L ;
Cohen, IJ ;
Aviner, S ;
Steinmetz, A ;
Stein, J ;
Goshen, Y ;
Yaniv, I .
JOURNAL OF CHILD NEUROLOGY, 2000, 15 (09) :573-580
[17]   TRANSIENT CEREBRAL-DYSFUNCTION SECONDARY TO HIGH-DOSE METHOTREXATE [J].
WALKER, RW ;
ALLEN, JC ;
ROSEN, G ;
CAPARROS, B .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (12) :1845-1850